bromocriptine has been researched along with dihydroergotamine in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (27.27) | 18.7374 |
1990's | 2 (18.18) | 18.2507 |
2000's | 3 (27.27) | 29.6817 |
2010's | 3 (27.27) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boess, FG; Monsma, FJ; Sleight, AJ | 1 |
Dantzig, AH; Ekins, S; Kim, RB; Lan, LB; Leake, BF; Schuetz, EG; Schuetz, JD; Shepard, RL; Wikel, JH; Winter, MA; Wrighton, SA; Yasuda, K | 1 |
Furuya, K; Lan, LB; Sanglard, D; Schuetz, EG; Schuetz, JD; Yasuda, K | 1 |
Pratim Roy, P; Roy, K | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Berde, B | 1 |
Loeffler, LJ; Schran, HF; Schwarz, HJ; Talbot, KC | 1 |
Kanto, J | 1 |
Delaforge, M; Mansuy, D; Peyronneau, MA; Renaud, JP; Riviere, R | 1 |
3 review(s) available for bromocriptine and dihydroergotamine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacology of ergot alkaloids in clinical use.
Topics: Animals; Brain Diseases; Bromocriptine; Dihydroergotamine; Dihydroergotoxine; Dopamine Antagonists; Ergot Alkaloids; Ergotamine; Female; Humans; Methysergide; Migraine Disorders; Parkinson Disease; Pituitary Gland; Prolactin; Receptors, Adrenergic; Receptors, Dopamine; Uterus; Vasoconstriction | 1978 |
Clinical pharmacokinetics of ergotamine, dihydroergotamine, ergotoxine, bromocriptine, methysergide, and lergotrile.
Topics: Absorption; Animals; Bromocriptine; Dihydroergotamine; Ergolines; Ergot Alkaloids; Ergotamine; Half-Life; Humans; Kinetics; Methysergide | 1983 |
8 other study(ies) available for bromocriptine and dihydroergotamine
Article | Year |
---|---|
Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor.
Topics: Adenylyl Cyclases; Amino Acid Substitution; Binding Sites; Binding, Competitive; Cell Line; Cyclic AMP; Humans; Ligands; Lysergic Acid Diethylamide; Mutagenesis, Site-Directed; Mutation; Receptors, Serotonin; Serotonin; Serotonin Receptor Agonists | 1998 |
Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Ergonovine; Fluoxetine; Humans; Models, Molecular; Oxytocics; Protein Conformation; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship; Swine; Transfection; Vinblastine | 2002 |
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dihydroergocryptine; Drug Interactions; Enzyme Inhibitors; Fluconazole; Humans; Mice; Mice, Knockout; Microsomes, Liver; Oxidoreductases, N-Demethylating; Recombinant Proteins; Reserpine; Swine; Tissue Distribution; Transfection; Vinblastine | 2002 |
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Topics: Algorithms; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Factor Analysis, Statistical; Least-Squares Analysis; Linear Models; Models, Molecular; Neural Networks, Computer; Quantitative Structure-Activity Relationship; Reproducibility of Results | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Specific radioimmunoassay of ergot peptide alkaloids in plasma.
Topics: Bromocriptine; Cross Reactions; Dihydroergotamine; Ergolines; Ergotamine; Humans; Radioimmunoassay; Structure-Activity Relationship | 1979 |
High affinity of ergopeptides for cytochromes P450 3A. Importance of their peptide moiety for P450 recognition and hydroxylation of bromocriptine.
Topics: Animals; Bromocriptine; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Dexamethasone; Dihydroergotamine; Ergolines; Humans; Hydroxylation; Isoenzymes; Lysergic Acid; Microsomes, Liver; Mixed Function Oxygenases; NADP; Oxidation-Reduction; Peptides; Rats; Recombinant Proteins; Saccharomyces cerevisiae; Substrate Specificity | 1994 |